Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Black Diamond Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 88
- −7 vs. Q3 2024
- Shares held
- 47.9M
- −782.9K (−1.6%) vs. Q3 2024
- Total value
- $102.5M
- −$109.2M (−51.6%) vs. Q3 2024
- New holders
- 21
- 35 more added
- Sold out
- 28
- 16 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 96 | $64.9M |
| Q1 2026 | 104 | $82.0M |
| Q4 2025 | 104 | $92.0M |
| Q3 2025 | 91 | $147.0M |
| Q2 2025 | 94 | $95.8M |
| Q1 2025 | 85 | $63.0M |
| Q4 2024 | 88 | $102.5M |
| Q3 2024 | 96 | $211.9M |
| Q2 2024 | 90 | $217.9M |
| Q1 2024 | 88 | $199.9M |
| Q4 2023 | 76 | $107.1M |
| Q3 2023 | 73 | $106.8M |
| Q2 2023 | 74 | $209.2M |
| Q1 2023 | 50 | $40.6M |
| Q4 2022 | 59 | $37.9M |
| Q3 2022 | 69 | $36.3M |
| Q2 2022 | 74 | $52.9M |
| Q1 2022 | 87 | $63.5M |
| Q4 2021 | 95 | $123.7M |
| Q3 2021 | 101 | $206.3M |
| Q2 2021 | 102 | $309.6M |
| Q1 2021 | 113 | $705.5M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Black Diamond Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Group One Trading, L.P. | 0 | $0 | 0.00% | −75,314−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −59,507−100.0% | Sold out |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −52,985−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −26,025−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −22,583−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −22,286−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −18,600−100.0% | Sold out |
| Vontobel Holding Ltd. | 0 | $0 | 0.00% | −15,723−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −15,692−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −12,355−100.0% | Sold out |
| Ausdal Financial Partners, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −4,300−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −227−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −83−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| GeoWealth Management, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Raymond James Financial Services Advisors, Inc. | – | – | – | – | Not filed |